ASTRAZENECA PLC ORD USD0.25
Symbol: AZN
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 20 Feb 2025 |
| Pay Date | 24 Mar 2025 |
| Total Dividends - Year to Date | 245.6 |
| Dividend Yield (%) | 2.1608 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 1.7740 |
| Market Cap (M) | 177113.6000 |
| Price/Earnings (PE) | 31.3372 |
| Earnings Per Share | 362.7 |
| Revenue Per Share | 26.7397 |
| Return on Equity % | 17.6031 |
1 Month Performance Chart
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy10 |
Buy15 |
Neutral4 |
Sell0 |
Strong Sell0 |
|---|---|---|---|---|---|
| Brokers | 10 | 15 | 4 | 0 | 0 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here |
0.30% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2024, AstraZeneca plc revenues increased 18% to $54.07B. Net income increased 18% to $7.04B. Revenues reflect Farxiga segment increase of 28% to $7.66B, Ultomiris segment increase of 32% to $3.92B, Tagrisso segment increase of 13% to $6.58B, United States segment increase of 20% to $21.81B, United Kingdom segment increase of 41% to $4.74B, Sweden segment increase of 34% to $2.29B.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/12/2024 |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
|---|---|---|---|---|---|---|
| Total Revenue | 54,073.00 | 45,811.00 | 44,351.00 | 37,417.00 | 26,617.00 | 24,384.00 |
| Gross profit | 44,415.00 | 37,743.00 | 35,702.00 | 27,875.00 | 21,347.00 | 19,560.00 |
| Operating Profit/Loss | 10,003.00 | 8,193.00 | 3,757.00 | 1,056.00 | 5,162.00 | 2,924.00 |
| Profit Before Tax | 8,691.00 | 6,899.00 | 2,501.00 | -265.00 | 3,916.00 | 1,548.00 |
| Profit After Tax | 7,041.00 | 5,961.00 | 3,293.00 | 115.00 | 3,144.00 | 1,227.00 |
| Equity Holders of Parent Company | 7,035.00 | 5,955.00 | 3,288.00 | 112.00 | 3,196.00 | 1,335.00 |
| Minority Interest | 79.00 | 17.00 | 16.00 | 16.00 | 68.00 | 1,577.00 |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/12/2024 |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 78,208.00 | 76,065.00 | 73,890.00 | 79,119.00 | 47,185.00 | 45,814.00 |
| Total Current Assets | 25,827.00 | 25,054.00 | 22,593.00 | 26,244.00 | 19,544.00 | 15,563.00 |
| Total Assets | 104,035.00 | 101,119.00 | 96,483.00 | 105,363.00 | 66,729.00 | 61,377.00 |
| Total Liabilities | 63,164.00 | 61,953.00 | 59,425.00 | 66,076.00 | 51,091.00 | 46,781.00 |
| Total Net Assets | 40,871.00 | 39,166.00 | 37,058.00 | 39,287.00 | 15,638.00 | 14,596.00 |
| Shareholders Funds | 40,786.00 | 39,143.00 | 37,037.00 | 39,268.00 | 15,622.00 | 13,127.00 |
| Minority Interests | 79.00 | 17.00 | 16.00 | 16.00 | 68.00 | 1,577.00 |
| Total Equity | 40,871.00 | 39,166.00 | 37,058.00 | 39,287.00 | 15,638.00 | 14,596.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy10 |
Buy15 |
Neutral4 |
Sell0 |
Strong Sell0 |
|---|---|---|---|---|---|
| Brokers | 10 | 15 | 4 | 0 | 0 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
© 2022 Refinitiv, an LSEG business. All rights reserved.
Forecasts
| Year | 2025 | 2026 |
|---|---|---|
| Revenue | £57,176.50mn | £60,621.80mn |
| Pre-tax-Profit | £17,894.70mn | £20,010.40mn |
| EPS | £6.94p | £7.82p |
| EPS Growth | 9.34% | 12.70% |
| P/E | 15.58 | 13.92 |
| PEG Ratio | 1.67 | 1.10 |
| Dividend | 251.79p | 264.00p |
| Yield | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
| Date | Broker | Recommendation | Price | Old Target | New Target | Change |
|---|---|---|---|---|---|---|
| 26th Mar 2025 | Berenberg Bank | Reiteration | 11232p | 0p | 140p | Buy |
| 7th Mar 2025 | Shore Capital | Reiteration | 12072p | 0p | 0p | Buy |
| 19th Feb 2025 | JP Morgan Cazenove | Reiteration | 11704p | 0p | 0p | Overweight |
| 27th Jan 2025 | Berenberg Bank | Reiteration | 11180p | 0p | 140p | Buy |
| 6th Jan 2025 | Berenberg Bank | Reiteration | 10712p | 0p | 140p | Buy |
| 22nd Nov 2024 | JP Morgan Cazenove | Reiteration | 10474p | 0p | 14000p | Overweight |
| 7th Nov 2024 | Shore Capital | Reiteration | 9725p | 0p | 0p | Buy |
| 7th Nov 2024 | JP Morgan Cazenove | Reiteration | 9725p | 0p | 14000p | Overweight |
| 16th Sep 2024 | JP Morgan Cazenove | Reiteration | 12016p | 0p | 0p | Overweight |
| 3rd Sep 2024 | Deutsche | Reiteration | 13190p | 0p | 11000p | Hold |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 2 Apr 2025 | 10:20 | 11,100 | 32 | Sell |
| 2 Apr 2025 | 10:19 | 11,100 | 42 | Buy |
| 2 Apr 2025 | 10:19 | 11,102 | 0 | Buy |
| 2 Apr 2025 | 10:19 | 11,099 | 249 | Unknown |
| 2 Apr 2025 | 10:19 | 11,096 | 24 | Buy |
| 2 Apr 2025 | 10:19 | 11,098 | 23 | Buy |
| 2 Apr 2025 | 10:19 | 11,098 | 35 | Buy |
| 2 Apr 2025 | 10:19 | 11,098 | 1 | Buy |
| 2 Apr 2025 | 10:19 | 11,096 | 20 | Buy |
| 2 Apr 2025 | 10:18 | 11,094 | 0 | Sell |
| 2 Apr 2025 | 10:18 | 11,096 | 31 | Sell |
| 2 Apr 2025 | 10:18 | 11,096 | 33 | Sell |
| 2 Apr 2025 | 10:18 | 11,100 | 38 | Buy |
| 2 Apr 2025 | 10:18 | 11,100 | 35 | Buy |
| 2 Apr 2025 | 10:18 | 11,100 | 23 | Buy |
| 2 Apr 2025 | 10:18 | 11,098 | 8 | Buy |
| 2 Apr 2025 | 10:18 | 11,098 | 24 | Buy |
| 2 Apr 2025 | 10:18 | 11,098 | 38 | Buy |
| 2 Apr 2025 | 10:18 | 11,098 | 38 | Buy |
| 2 Apr 2025 | 10:18 | 11,098 | 34 | Buy |
Selected data supplied by Thomson Reuters © View restrictions.